From cancerpage.com (via Reuters):
Investigational GnRH Blocker Shows Potential for Advanced Prostate Cancer
By Jill Stein
MILAN MAR 27, 2008 (Reuters Health) – The investigational gonadotropin-releasing hormone (GnRH) antagonist degarelix is as effective as standard androgen deprivation therapy in men with prostate cancer, according to phase III results announced at the 23rd Annual Meeting of the European Association of Urology (EAU). <snip>
“The findings clearly suggest that degarelix is a superior androgen deprivation therapy over a GnRH agonist and that the new drug rivals orchidectomy in terms of efficacy but without the adverse psychological outcomes,” Mr. John Anderson, consultant urologic surgeon at the Royal Hallamshire Hospital in Sheffield, UK, said in a news conference.
“In fact,” he noted, “usually about 80% of men choose medical over surgical castration, and this new agent seems to be a better form of medical castration than the gold standard androgen deprivation therapy.”
Leave A Comment